Reuters
  Gilead Sciences Inc. said on Monday its antiviral drug  remdesivir  showed improvement in patients with moderate COVID-19 in a late-stage study.
  Remdesivir is being closely watched after the U.S. Food and Drug Administration granted emergency use authorization last month, citing results from another study run by the National Institutes of Health that showed the drug reduced hospitalization stays by 31 percent, or about four days, compared to a placebo.
  Read more.  
 